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Abstract  The  eight-item  Morisky  Medication  Adherence  Scale  (MMAS-8)  is  a  structured  self-
report measure  of  medication-taking  behavior  that  has  been  widely  used  in  various  cultures.
In Spain,  no  studies  to  date  have  analyzed  the  psychometric  properties  of  the  scale  in  psychi-
atric care.  The  purpose  of  the  present  instrumental  study  was  to  determine  the  psychometric
properties  of  the  Spanish  version  of  the  MMAS-8  in  a  sample  of  967  consecutive  psychiatric
outpatients.  The  scale  showed  adequate  construct  validity  and  results  pointed  to  a  one-factor
solution  in  which  all  the  items  contributed  to  the  ﬁnal  index  of  adherence.  The  MMAS-8  exhib-
ited signiﬁcant  correlation  coefﬁcients  with  the  10-item  Drug  Attitude  Inventory,  Form  C  of  the
Multidimensional  Health  Locus  of  Control  scale,  and  the  Hong  Psychological  Reactance  Scale.
Moreover, the  MMAS-8  was  able  to  differentiate  between  various  mental  disorder  diagnosis
groups. The  ﬁndings  of  this  study  suggest  that  the  Spanish  version  of  the  MMAS-8  is  a  reliable
and valid  measure  of  medication  adherence  that  can  be  used  in  a  psychiatric  outpatient  setting.
© 2014  Asociación  Espan˜ola  de  Psicología  Conductual.  Published  by  Elsevier  España,  S.L.U.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
PALABRAS  CLAVE
Escala  de  Adherencia
a  la  Medicación  de
Propiedades  psicométricas  de  la  Escala  Morisky  de  Adherencia  a  los  Medicamentos
(MMAS-8-ítems)  en  pacientes  psiquiátricos  ambulatoriosMorisky-8  ítems; Resumen  La  Escala  de  Adherencia  a  la  Medicación  de  Morisky-8  ítems  (MMAS-8)  es  una  medidapropiedades
psicométricas;
pacientes
psiquiátricos;
auto-informada  estructurada  de  la  conducta  de  toma  de  la  medicación  ampliamente  utilizada  en
diferentes  culturas.  No  existen  estudios  en  Espan˜a  que  analicen  sus  propiedades  psicométricas
en población  psiquiátrica.  El  objetivo  de  este  estudio  es  determinar  las  propiedades  psicométri-
cas de  la  versión  espan˜ola  de  la  MMAS-8  en  una  muestra  de  967  pacientes  psiquiátricos  en
régimen ambulatorio.  Los  resultados  mostraron  una  adecuada  validez  de  constructo,  con  unaestudio  instrumental
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clara  tendencia  a  una  solución  monofactorial,  donde  todos  los  ítems  colaboraron  en  el  índice
ﬁnal de  adherencia.  MMAS-8  alcanzó  correlaciones  signiﬁcativas  con  el  Inventario  de  Actitudes
hacia la  Medicación-10  ítems,  con  la  forma  C  de  la  Escala  Multidimensional  de  Locus  de  Control
sobre la  Salud  y  la  Escala  de  Reactancia  Psicológica.  También  la  MMAS-8  permitió  diferenciar  el
nivel de  adherencia  entre  diferentes  trastornos  psicopatológicos.  Los  hallazgos  de  este  estudio
indican que  la  MMAS-8  es  una  medida  ﬁable  y  válida  para  evaluar  la  adherencia  a  la  medicación
y que  puede  ser  utilizada  con  muestras  de  pacientes  psiquiátricos.
© 2014  Asociación  Espan˜ola  de  Psicología  Conductual.  Publicado  por  Elsevier  España,  S.L.U.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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ANon-adherence  to  well-prescribed  psychiatric  medica-
ions  compromises  the  effectiveness  of  available  treatments
nd  has  been  associated  with  poor  treatment  outcomes  such
s  increased  risk  of  relapse  and  recurrence  as  well  as  higher
ealth-care  costs  (Geddes,  Carney,  &  Davies,  2003;  Velligan
t  al.,  2009,  2010).  At  present,  the  extent  to  which  patients
ollow  psychiatric  advice  is  a  major  concern  and  an  impor-
ant  challenge  to  the  practice  of  psychiatry.  In  fact,  rates  of
on-adherence  to  medication  in  psychiatric  patients  range
etween  28  and  52%  in  patients  with  major  depressive  dis-
rder,  20  and  50%  in  patients  with  bipolar  disorder,  and  20
nd  72%  in  patients  with  schizophrenia  (Julius,  Novitsky,  &
ubin,  2009).
Currently,  there  is  no  ‘gold  standard’  measure  of  med-
cation  adherence,  given  that  all  the  measures  available
ave  their  limitations  (Osterberg  &  Blaschke,  2005).  Non-
dherence  can  be  measured  directly  or  indirectly.  Direct
ethods  of  assessing  medication  non-adherence  detect  the
resence  of  the  drug  in  a  patient’s  body  using  assays  for  the
rug,  drug  metabolites,  or  other  markers  in  urine,  blood,  or
ther  bodily  ﬂuids.  However,  such  methods  are  rarely  used
ecause  of  their  high  cost  and  inability  to  provide  feedback
t  the  point  of  care  (Voils,  Hoyle,  Thorpe,  Maciejewski,  &
ancy,  2011).  Moreover,  their  results  can  be  inﬂuenced  by
actors  other  than  adherence  such  as  drug  or  food  inter-
ctions,  physiological  variability,  dosing  schedules,  and  the
alf-life  of  drugs  (Roberts  &  Turner,  1988;  Smith,  Psaty,
eckbert,  Tracy,  &  Cornell,  1999).  Indirect  methods  mea-
ure  medication  non-adherence  by  analyzing  behavior.  They
nclude  electronic  drug  monitoring,  pill  counts,  pharmacy
eﬁlls,  medical  record  review,  directly  observed  therapy,
linician  assessment,  and  self-reports.  The  poor  availability
nd  high  cost  of  electronic  monitoring  of  dosing  schedules
imit  the  feasibility  of  this  method  (Choo  et  al.,  1999).  As
egards  pill  counts,  prescriptions  may  be  ﬁlled  some  time
efore  needed  and  patients  may  not  accurately  recall  the
ate  medications  were  started;  drugs  may  not  be  stored
n  their  original  containers  and/or  tablets  from  other  bot-
les  may  be  added  to  the  new  container  (Shelly,  Vik,  &
axwell,  2005).  Although  self-reports  carry  a  potential  risk
f  misstatements  or  response  biases,  they  provide  a  reason-
bly  accurate  estimate  of  adherence  (Osterberg  &  Blaschke,
005).  Self-reports  have  the  following  advantages:  they  are
rief,  inexpensive,  and  applicable  in  various  settings.  In
ddition,  they  can  provide  immediate  feedback  at  the  point
f  care  and  reveal  underlying  issues  that  contribute  to  non-
dherence  (Voils  et  al.,  2011).
t
a
iThe  eight-item  Morisky  Medication  Adherence  Scale
MMAS-8)  (Morisky,  Ang,  Krousel-Wood,  &  Ward,  2008)  is  a
tructured  self-report  measure  of  medication-taking  behav-
or.  It  was  developed  from  a  previously  validated  four-item
cale  (Morisky,  Green,  &  Levine,  1986) and  supplemented
ith  additional  items  addressing  the  circumstances  sur-
ounding  adherence  behavior.  This  measure  was  designed
o  facilitate  the  recognition  of  barriers  to  and  behaviors
ssociated  with  adherence  to  chronic  medications  such  as
sychiatric  drugs.  The  scale  provides  information  on  behav-
ors  related  to  medication  use  that  may  be  unintentional
e.g.,  forgetfulness)  or  intentional  (e.g.,  not  taking  medi-
ations  because  of  side  effects).  Besides  its  authors,  other
esearchers  (e.g.,  Gupta  &  Goren,  2013)  have  provided  evi-
ence  of  good  psychometric  properties  of  the  scale.  The
MAS-8  is  currently  available  in  33  languages  and  is  widely
sed  in  various  types  of  studies  (i.e.,  Al-Qazaz  et  al.,  2010;
im  et  al.,  2014;  Yan  et  al.,  2014).
The  purpose  of  this  study  was  to  explore  the  psycho-
etric  properties  of  the  Spanish  version  of  the  eight-item
orisky  Medication  Adherence  Scale  (MMAS-8)  in  a  psychi-
tric  outpatient  setting.  We  are  aware  of  the  debate  about
he  appropriateness  of  certain  diagnostic  labels  (Pemberton
 Wainwright,  2014;  Robles  et  al.,  2014),  including  pro-
osals  for  eliminating  such  labels  (Timimi,  2014).  In  this
tudy,  however,  we  used  the  major  psychiatric  diagno-
is  labels  mainly  for  communication  purposes.  Speciﬁcally,
e  will  examine  the  internal  structure  of  MMAS-8  (with
oth  exploratory  and  conﬁrmatory  factor  analyses).  For
xternal  evidences,  MMAS-8  will  be  related  or  contrasted
ith  (i)  socio-demographic  and  contextual  variables,  usually
ssociated  with  adherence  to  treatment  (gender,  age,  edu-
ational  level,  treatment  duration,  treatment  complexity,
nd  psychiatric  diagnosis);  and  (ii)  psychological  processes
self-efﬁcacy,  health  locus  of  control,  and  psychological
eactance).  Attitude  toward  drugs  was  used  a  criterion  for
dherence.
ethod
articipants
 ﬁnal  sample  of  967  psychiatric  patients  accepted  to  par-
icipate  in  this  study.  Table  1  shows  the  sample  distribution
ccording  to  the  socio-demographic  and  clinical  variables
ncluded  in  the  research.
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Table  1  Socio-demographic  and  clinical  characteristics  of  the  sample  (N  =  967).
Variable Category  Number  of  patients  %  of  the  sample
Age  18-30  years  99  10.2
30-45 years  262  27.1
Mean age:  49.6  ±  13.8  years  45-60  years  406  42.0
Range: 18-87  years  60-75  years  169  17.5
>75 years 30  3.1
Sex Male  358  37.1
Female  608  62.9
Educational  level No  formal  education 88  9.1
Primary  education  334  34.5
Secondary  education  359  37.1
University  studies  186  19.2
ICD-10 diagnosis*  Schizophrenia  179  18.5
Bipolar disorder  118  12.2
Depressive  disorder  462  47.8
Anxiety  disorders  160  16.5
Personality  disorders  30  3.1
Other diagnoses  18  1.9
History of  psychiatric  No  641  66.3
admissions 1  121  12.5
2 68  7.0
59.6% involuntary  admissions  3  51  5.3
≥4 86  8.9
No. of  psychiatrists  1  323  33.4
2 259  26.8
Mean: 2.7  ±  2.0  3  147  15.2
Range: 1-15  4  79  8.2
≥5 159  16.3
Psychotropic  drugs  No  drugs  21  2.2
One drug  128  13.2
Mean: 2.9  ±  1.4  drugs  Two  drugs  260  26.9
Range: 0-8  Three  drugs  246  25.4
Polypharmacy:  86.2%  Four  drugs  172  17.8
Five or  more  drugs  140  14.5
Treatment Antidepressants  667  69.0
Tricyclic 33  3.4
SSRIs 502  51.9
SNSRIs 340  35.2
Benzodiazepines  763  79.0
Antipsychotics  327  33.8
Conventional  48  5.0
Atypical  315  32.6
Mood stabilizers  275  28.4
Anticholinergics  43  4.4
ive N
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oNote. ICD = International Classiﬁcation of Diseases; SNSRIs = Select
Serotonin Reuptake Inhibitors.
Instruments
We  assessed  age,  sex,  educational  level  (no  formal  educa-
tion,  primary  studies,  secondary  studies,  university  studies),
history  as  a  psychiatric  patient  (in  years),  and  type  of  psy-
choactive  drugs  currently  taken.  For  evaluation  purposes,
medications  were  divided  into  the  common  groups  of  psy-
chotropic  drugs:  antidepressants  (tricyclic  antidepressants,
selective  serotonin  reuptake  inhibitors--SSRIs--and  serotonin
and  norepinephrine  selective  reuptake  inhibitors--SNSRIs--),
benzodiazepines,  antipsychotic  drugs  (conventional  and
p
t
voradrenaline and Serotonin Reuptake Inhibitors; SSRIs = Selective
typical),  mood  stabilizers,  and  anticholinergics.  We  also
ecorded  how  long  patients  had  received  psychiatric  treat-
ent  (in  months),  the  number  of  psychiatrists  who  had
reated  them  during  that  time,  and  the  number  of  psychi-
tric  admissions,  specifying  whether  they  were  voluntary
r  involuntary.  Diagnoses  and  treatment  information  were
btained  through  the  prescription  sheet  provided  to  all
atients  after  their  psychiatric  consultation,  which  included
he  diagnosis  and  each  prescription  given.
Medication  adherence  was  tested  using  the  Spanish
ersion  of  the  validated  eight-item  self-report  Morisky
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edication  Adherence  Scale  (MMAS-8)  (Morisky  et  al.,  2008;
ppendix  1).  Questions  are  formulated  to  avoid  a  ‘‘yes-
aying’’  bias  (i.e.,  the  wording  of  Item  5  is  reversed  to
revent  the  tendency  to  respond  the  same  way  to  a  series  of
uestions  regardless  of  their  content).  Response  choices  are
‘yes’’  or  ‘‘no’’  for  items  1  through  7  and  Item  8  has  a  ﬁve-
oint  Likert  response  scale.  Each  ‘‘no’’  response  is  rated  as
 and  each  ‘‘yes’’  response  is  rated  as  0  except  for  item  5,
n  which  each  ‘‘yes’’  response  is  rated  as  1  and  each  ‘‘no’’
esponse  is  rated  as  0.  For  Item  8,  the  code  (0-4)  has  to  be
tandardized  by  dividing  the  result  by  4  to  calculate  a sum-
ated  score.  Total  scores  on  the  MMAS-8  range  from  0  to  8,
ith  scores  of  8  reﬂecting  high  adherence,  7  or  6  reﬂecting
edium  adherence,  and  <6  reﬂecting  low  adherence.  Per-
ission  to  use  the  scale  was  granted  by  Donald  Morisky,  the
opyright  holder  of  the  instrument.
Four  self-report  questionnaires  were  used  as  validity
riteria  in  the  study:  the  Hong  Psychological  Reactance  Scale
HPRS),  Form  C  of  the  Multidimensional  Health  Locus  of  Con-
rol  scale  (MHLC-C),  the  General  Self-Efﬁcacy  Scale  (GSE),
nd  the  10-item  Drug  Attitude  Inventory  (DAI-10).
The  Hong  Psychological  Reactance  Scale  (Hong  &  Faedda,
996)  is  a  14-item  self-report  questionnaire  that  was
eveloped  to  measure  individual  differences  in  reactance
roneness,  that  is,  individuals’  trait  propensity  to  experi-
nce  psychological  reactance.  According  to  the  concept  of
sychological  reactance  (Hong  &  Faedda,  1996),  when  an
ndividual’s  freedom  is  threatened,  the  individual  will  be
otivated  to  restore  his  or  her  perceived  loss  of  freedom.
articipants  indicated  the  extent  to  which  they  endorsed
ach  cognitive  or  affective  statement  on  a  ﬁve-point  Lik-
rt  scale  (from  1  =  strongly  disagree  to  5  =  strongly  agree).
n  our  study  we  used  the  validated  Spanish  version  of  the
cale  (Cronbach’s  alpha:  Affective  Psychological  Reactance=
76;  Cognitive  Psychological  Reactance=  .62)  (De  las  Cuevas,
en˜ate,  Betancort,  &  De  Rivera,  2014).
Form  C  of  the  Multidimensional  Health  Locus  of  Control
cale  (MHLC-C;  Wallston,  Stein,  &  Smith,  1994)  was  used
o  assess  patients’  perception  about  who  or  what  controls
heir  depression  outcomes.  The  MHLC-C  is  an  18-item  gen-
ral  purpose,  condition-speciﬁc  locus  of  control  self-report
cale  that  can  easily  be  adapted  for  use  with  any  medical
r  health-related  condition  to  assess  individuals’  beliefs  on
hat  inﬂuences  their  health.  It  is  composed  of  four  sub-
cales:  an  internal  locus  of  control  subscale--Internality--and
hree  external  locus  of  control  scales--Chance, Doctors,
nd  Other  (powerful)  People--that  measure  control  varia-
les  with  regard  to  participants’  health.  Each  item  includes
 belief  statement  about  the  patient’s  medical  condition
ith  which  she/he  may  agree  or  disagree  through  a  six-
oint  Likert  scale  ranging  from  strongly  disagree  (1)  to
trongly  agree  (6).  We  used  the  validated  Spanish  version
f  the  scale  (Cronbach’s  alpha:  Internal  =  .67;  Chance  =  .62;
octors  =  .58;  Other  People  =  .41)  (Doku-Ramírez,  Fonseca-
arra,  González-Gil,  Gualdrón-Alba,  &  Cifuentes-Villalobos,
012).
The  General  Perceived  Self-Efﬁcacy  Scale  (GPSE;
chwarzer  &  Jerusalem,  1995)  is  a  ten-item  self-report  scale
hat  measures  general  self-efﬁcacy  as  a  prospective  and
perative  construct.  In  contrast  with  other  scales  that  were
esigned  to  assess  optimism,  this  scale  explicitly  refers  to
ersonal  agency,  that  is,  the  belief  that  our  own  actions
R
A
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re  responsible  for  successful  outcomes.  Each  item  is  scored
rom  1  (not  at  all  true) to  4  (completely  true). The  summary
core  ranges  from  10  to  40,  with  highest  scores  indicating
igh  self-efﬁcacy.  We  used  the  validated  Spanish  version  of
he  scale  (Cronbach’s  alpha=  .90)  (Bäßler  &  Schwarzer,  1996;
anjuán,  Pérez,  &  Bermúdez,  2000).
The  ten-item  Drug  Attitude  Inventory  (DAI-10;  Hogan,
wad,  &  Eastwood,  1983)  was  developed  to  measure  subjec-
ive  responses  and  attitudes  of  psychiatric  patients  toward
heir  treatment.  It  indicates  whether  patients  are  satisﬁed
ith  their  medication  and  evaluates  their  understanding  of
ow  the  treatment  is  affecting  them.  The  inventory  has  ten
ighly  speciﬁc  items  of  subjective  experience  presented  as
elf-report  statements  with  which  the  patient  agrees  or  dis-
grees.  Response  options  are  true/false,  and  each  response
s  scored  as  +1  if  correct  or  -1  if  incorrect.  The  ﬁnal  score  is
he  grand  total  of  positive  and  negative  points.  Total  scores
omprise  values  from  -10  to  10,  with  higher  scores  indicating
ore  positive  attitudes  toward  medication.  A  positive  total
core  means  a  positive  subjective  response  while  a  negative
otal  score  means  a negative  subjective  response.  The  DAI-
0  has  been  found  to  be  correlated  with  both  clinician-rated
dherence  and  biochemical  measures  of  adherence  (Nielsen,
indström,  Nielsen,  &  Levander,  2012).  In  this  study,  the  DAI-
0  scale  was  used  as  a  validity  criterion  of  adherence.  We
sed  the  validated  Spanish  version  of  the  scale  (Cronbach’s
lpha=  .67;  Robles  García,  Salazar  Alvarado,  Páez  Agraz,  &
amírez  Barreto,  2004).
rocedure
rom  October  2013  to  May  2014,  1,220  consecutive  psy-
hiatric  outpatients  who  attended  two  Community  Mental
ealth  Centers  on  Tenerife  Island  (Canary  Islands,  Spain)
ere  invited  to  participate  in  the  study;  of  these,  967
ccepted.  70%  of  patients  who  refuse  to  participate  reported
hat  they  have  no  time  to  participate  while  30%  give  no
xplanation  about.  Interviews  were  held  in  the  waiting
oom  previously  to  patients’  psychiatric  consultation  dur-
ng  a  period  of  about  25  minutes.  Participants  received  a
ull  explanation  of  the  study,  after  which  they  signed  an
nformed  consent  document  that  had  been  approved  by  the
ocal  ethics  committee.  Next,  participants  ﬁlled  out  a  brief
ocio-demographic  and  clinical  survey  and  completed  the
-item  Morisky  Medication  Adherence  Scale.
ata  analysis
arious  statistical  analyses  were  conducted.  Frequency  anal-
ses  were  used  to  describe  the  sample.  To  analyze  the
nternal  structure  of  MMAS-8,  both  exploratory  and  con-
rmatory  factor  analyses  were  performed.  For  external
vidences,  depending  the  nature  of  variables,  different
trategies  were  used:  for  continuous  variables,  Pearson
orrelation  analyses  were  executed;  and  for  dichotomous
ariables,  ANOVAs  and  chi-square  tests  were  used  to  conduct
ntergroup  comparisons  when  needed.esults
 two-step  analysis  strategy  was  carried  out  to  determine
he  factorial  structure  of  MMAS-8.  First,  an  exploratory
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Table  2  Factor  structure  of  the  MMAS-8.  Oblique  (oblimin)  rotation  of  the  initial  factor  extraction  using  the  principal  component
method. 50%  random  sample  (n  =  480).
Items  Rotation  factors
1  2
1.  Do  you  sometimes  forget  to  take  your  [health  concern]  pills?  .67  .32
2. People  sometimes  miss  taking  their  medications  for  reasons  other  than  forgetting.  Thinking
over the  past  two  weeks,  were  there  any  days  when  you  did  not  take  your  [health  concern]
medicine?
.76 .13
3. Have  you  ever  cut  back  or  stopped  taking  your  medication  without  telling  your  doctor,
because you  felt  worse  when  you  took  it?
.64  .29
4. When  you  travel  or  leave  home,  do  you  sometimes  forget  to  bring  along  your  [health
concern]  medication?
.45  −.10
5. Did  you  take  your  [health  concern]  medicine  yesterday?  .63  −.23
6. When  you  feel  like  your  [health  concern]  is  under  control,  do  you  sometimes  stop  taking
your medicine?
.64  −.01
7. Taking  medication  everyday  is  a  real  inconvenience  for  some  people.  Do  you  ever  feel
hassled about  sticking  to  your  [health  concern]  treatment  plan?
.08  .92
8. How  often  do  you  have  difﬁculty  remembering  to  take  all  your  medications?  .80  .12
Eigenvalue 3.12  1.05
% of  variance 39.05  13.15
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sfactor  analysis  (EFA)  was  carried  out  with  a  random  sam-
ple  (50%).  Second,  a  conﬁrmatory  factor  analysis  (CFA)  was
performed  with  the  rest  of  the  sample  to  test  the  structure
found  with  EFA.
The  items  of  the  MMAS-8  were  subjected  to  exploratory
factor  analysis.  A  principal  component  analysis  was  used
to  extract  the  factors  of  the  measure.  An  oblique  rotation
method  was  selected  because  there  were  potential  corre-
lations  between  items  measuring  the  same  construct.  The
structure  obtained  a  Kaiser-Meyer-Olkin  coefﬁcient  of  .83,
with  a  2(28)  =  875.68,  p  =  .000.  These  data  indicated  that  it
was  possible  to  conduct  the  factor  analysis.  Table  2  summa-
rizes  the  factor  structure  obtained.
Results  showed  a  two  factor  solution,  but,  as  can  be
observed,  results  tend  to  a  one-factor  solution:  using  an
item  selection  criterion  of  ≥.30  loading  coefﬁcients,  only
one  item  did  not  fall  within  the  one-factor  solution.  It  was
Item  7,  which  dealt  with  an  emotional  aspect  of  adherence
(i.e.,  feeling  hassled  about  treatment  schedule).  Internal
consistency  (Cronbach’s  alpha)  reached  a  level  of  .75.  This
coefﬁcient  increased  slightly  if  Item  7  was  deleted  (  =  .77),
and  the  item-total  correlation  for  this  item  was  .16,  which
was  highly  signiﬁcant  (p  =  .000).  The  contribution  of  the  var-
ious  items  to  the  total  score  on  the  MMAS-8  was  always
signiﬁcant.
In  this  sense,  it  was  tested,  with  a  CFA  strategy,  two
one-factor  solutions:  one  with  all  the  eight  items,  and  one
without  item  seven.  For  that,  the  rest  of  50%  random  sample
was  used.  The  coefﬁcients  obtained  are  collected  in  Table  3.
Both  models  achieved  acceptable  levels  of  adjust  (except
chi  square),  with  better  coefﬁcients  for  a  solution  without
item  seven.To  analyze  the  contribution  of  each  item  to  the  total
score  of  the  MMAS-8,  we  deleted  each  item  one  by  one  and
compared  the  scores  on  the  MMAS-8  of  the  three  adherence
groups:  high  adherence  (HA),  medium  adherence  (MA),  and
z
w
aow  adherence  (LA).  In  all  cases,  deleting  any  items  resulted
n  a  signiﬁcance  decrease  in  the  MMAS-8  total  score.  ANOVAs
ielded  the  following  coefﬁcients  when  the  following  items
ere  deleted:  item  1,  F (2,  948)  =  1179.65,  p  =  .000;  item  2,
 (2,  948)  = 1743.15,  p  =  .000;  item  3,  F  (2,  948)  =  1415.92,
 =  .000;  item  4,  F  (2,  948)  =  2050.68,  p  =  .000;  item  5,  F
2,  948)  =  2128.71,  p  =  .000;  item  6,  F  (2,  948)  =  2046.32,
 =  .000;  item  7,  F (2,  948)  =  1289.34,  p  =  .000;  and  item  8,  F
2,  948)  =  1832.88,  p  =  .000.
Considering  attitudes  toward  medication  (DAI-10  scale)
s  an  adherence-to-treatment  criterion,  correlations  with
he  items  of  the  MMAS-8  and  the  total  score  were  as  fol-
ows:  .12  with  item  1;  .17  with  item  2;  .22  with  item  3;
09  with  item  4;  .16  with  item  5;  .18  with  item  6;  .25  with
tem  7;  .25  with  item  8;  and  .30  with  the  total  score.  All
hese  coefﬁcients  reached  statistical  signiﬁcance  (p  =  .01).
he  ANOVA  included  only  949  patients  since  18  patients  did
ot  complete  the  DAI-10  as  they  were  not  currently  taking
ny  psychiatric  drug.
In addition,  to  test  whether  the  three  adherence  groups
ccording  to  the  MMAS-8  scored  signiﬁcantly  differently
n  attitudes  toward  medication,  we  performed  an  ANOVA.
esults  revealed  that  236  patients  were  classiﬁed  into  the
A  group,  with  a  mean  score  (M)  in  the  DAI-10  = 5.19
standard  deviation,  SD  =  3.77);  444  were  classiﬁed  into  the
A  group,  M  =  3.6  (SD  =  3.79);  and  269  were  classiﬁed  into
he  LA  group,  M  =  1.96  (SD  =  4.38).  The  coefﬁcients  obtained
eached  statistical  signiﬁcance  (F  (2,  948)  =  41.7;  p  =  .000),
ith  a moderate  effect  size  (2 =  .081);  patients  with  greater
dherence  obtained  higher  scores  in  positive  attitude  to
rugs.  Anyway,  cautions  must  be  taken  because  DAI  total
core  had  not  a  normal  distribution  (Kolmogorov-Smirnov’s =  4.48,  p  =  .000).
To  assess  external  evidences  of  validity,  the  MMAS-8
as  compared  to  various  socio-demographic  variables,  such
s  gender,  age,  educational  level,  treatment  duration  (in
126  C.  De  las  Cuevas  and  W.  Pen˜ate
Table  3  Conﬁrmatory  factor  analyses  (CFA)  of  MMAS-8,  testing  two  models  of  one-factor  solutions.  50%  random  sample  (n  =  479).
One-factor  model  X2  DF  P  RMSEA  GFI  CFI
8  items  132.75  36  .000  0.06  0.99  0.90
Without item  7  104.77  28  .000  0.05  0.99  0.94
Note. 2 = Chi square; DF = Degree of freedom; p = probability; RMSEA = Root Mean Square Error of Approximation; GFI = Goodness of Fit
Index; CFI = Comparative Fit Index.
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ponths),  treatment  complexity  (i.e.,  number  of  different
rugs  prescribed),  and  diagnosis  group.  No  differences  were
btained  in  the  MMAS-8  total  score  as  a  function  of  gender
F  (2,  948)  =  2.07)  or  adherence  group  (i.e.,  high,  medium,
ow):  2 (2)  =  3.99)].  However,  a  signiﬁcant  correlation  was
ound  between  the  scale  and  age  (rxy =  .19;  p  =  .000):  adher-
nce  increased  with  patient  age.  No  signiﬁcant  correlations
ere  found  as  a  function  of  educational  level  (rxy =  .04),
reatment  complexity  (rxy =  -.01),  or  treatment  duration
rxy =  .05).  Yet,  when  the  statistical  analysis  was  conducted
onsidering  the  level  of  adherence,  we  found  signiﬁcant
ifferences  between  the  three  groups  as  a  function  of
reatment  duration  (F  (2,  948)  =  4.75,  p  =  .003;  2 =  .01).
onferroni  tests  revealed  that  patients  with  high  adherence
M  =  118.65  months,  SD  =  112.16)  and  patients  with  medium
dherence  (M  =  121.17,  SD  =  120.72)  underwent  longer  treat-
ents  than  those  with  low  adherence  (M  95.54,  SD  =  94.09).
owever,  the  high  standard  deviation  indicates  that  these
ata  should  be  taken  with  caution,  as  they  show  an  irregular
istribution  of  scores.
As  regards  diagnosis  groups,  an  ANOVA  revealed  that
he  MMAS-8  was  able  to  differentiate  between  the  ﬁve
ajor  groups  of  disorders  (i.e.,  schizophrenia,  bipolar
isorder,  depression,  anxiety,  and  personality  disorders):
 (4,  932)  =  6.35;  p  =  .000;  2 =  .027).  According  to  the
onferroni  test,  patients  with  bipolar  disorder  exhibited
he  highest  adherence  (M  =  6.8,  SD  =  1.42).  This  score  was
igniﬁcant  higher  than  that  of  patients  with  personality  dis-
rders  (M  =  5.35,  SD  =  1.58)  and  anxiety  disorders  (M  =  6.13,
D  =  1.7).  In  addition,  patients  with  schizophrenia  (M  =  6.41,
D  =  1.42)  and  patients  with  depressive  disorders  (M  =  6.36,
34.2
23.5 26 18.3
6.7
47.9
46.9 47.4
48.4
43.3
17.9
29.6 26.7 33.3
50
0
10
20
30
40
50
60
70
80
90
100
DepressionSchizophreniaBipolar PersonalityAnxiety
Low Medium High
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aD  =  1.62)  scored  higher  than  patients  with  personality  dis-
rders.  Figure  1  shows  the  percentages  of  patients  (per
iagnosis)  with  high,  medium  and  low  levels  of  adher-
nce.  Such  percentages  were  statistically  signiﬁcant  (2
8)  =  22.77,  p  =  .004).
Finally,  we  performed  correlations  between  the  MMAS-
 and  three  different  psychological  processes  that  may
ffect  adherence:  level  of  self-efﬁcacy,  health  locus  of  con-
rol,  and  psychological  reactance.  Table  3 summarizes  the
oefﬁcients  obtained.
Although  the  MMAS-8  seemed  to  be  independent  of
elf-efﬁcacy,  it  exhibited  correlations  with  health  locus  of
ontrol  and  psychological  reactance.  According  to  health
ocus  of  control,  adherence  was  positively  correlated  with
atients’  conﬁdence  in  their  doctors  and  negatively  cor-
elated  with  patients’  belief  that  their  health  depends
n  chance.  Adherence  was  negatively  correlated  with
atients’  belief  that  their  health  depends  on  themselves.
sychological  reactance  was  negatively  correlated  with
dherence,  which  decreased  as  reactance--both  affective
nd  cognitive--increased.
iscussion
o  our  knowledge,  this  is  the  ﬁrst  study  that  evaluated
he  psychometric  properties  of  MMAS-8  among  psychiatric
atients.  The  original  MMAS-8  was  tested  by  Morisky  et  al.
2008)  on  a  sample  of  hypertensive  patients,  and  it  was
ound  that  the  scale  was  reliable  with  good  predictive
alidity  and  sensitivity.  Other  studies  had  evaluate  the
ight-item  MMAS  in  hypertensive  patients  (De  Oliveira-Filho,
oriski,  Neves,  Costa,  &  De  Lyra,  2014;  Hacıhasanog˘lu-As¸ılar,
özüm,  Capık  &  Morisky,  2014;  Korb-Savoldelli  et  al.,  2012),
n  patients  taking  warfarin  (Wang,  Kong,  &  Ko,  2012),  in
yocardial  infarction  patients  (Yan  et  al.,  2014),  in  diabetes
atients  (Sakthong,  Chabunthom,  &  Charoevisuthiwongs,
009),  in  HIV-positive  patients  (Södergârd  et  al.,  2006),
nd  in  patients  with  Parkinson’s  disease  (Fabbrini  et  al.,
013).  Most  of  these  studies  had  shown  satisfactory  psycho-
etric  properties,  with  good  convergent  validity  with  good
est--retest  reliability  and  with  acceptable  sensitivity  and
peciﬁty  (Table  4).
The  main  objective  of  this  paper  was  to  report  the  psy-
hometric  properties  of  the  Spanish  version  of  the  MMAS-8
n  a  sample  of  outpatients  with  psychiatric  disorders.  The
MAS-8  scale  is  relatively  simple  and  practical  to  use  in
ental  health  clinical  settings.  Leaving  aside  the  prob-
ems  inherent  to  Likert-type  scales,  which  can  confound
ome  results  (i.e.,  Hartley,  2014),  the  MMAS-8  scale  showed
dequate  construct  validity,  with  a  clear  trend  toward  a
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Table  4  Correlation  coefﬁcients  between  total  scores  on  the  MMAS-8  and  three  psychological  processes:  self-efﬁcacy,  health
locus of  control,  and  psychological  reactance.
Self-efﬁcacy  Health  locus  of  control  Psychological  reactance
Internal  Chance  Doctors  Other  people  Affective  Cognitive
rxy .041  −.14  −.16  .19  −.02  −.20  −.20
p .210  .000  .000  .000  .620  .000  .000
Note. rxy = Pearson correlation coefﬁcient; p = probability.
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Bone-factor  solution;  all  the  items  contributed  to  the  ﬁnal
index  of  adherence.  However,  Item  7,  the  only  item  related
to  emotions  about  drug  adherence  (instead  of  behavioral
adherence)  did  not  clearly  fall  within  the  one-factor  struc-
ture,  perhaps  because  it  is  more  related  to  attitudes  toward
medication  than  to  behaviors  directly  related  to  adher-
ence.  More  speciﬁc  analyses  should  be  conducted  about
this.
As  regards  criterion  validity,  the  scale  showed  signiﬁcant
correlations  with  positive  attitudes  of  patients  toward  their
treatment,  revealing  that  as  patients  become  more  satis-
ﬁed  with  their  medication  they  start  to  better  understand
how  the  treatment  is  helping  them  and  increase  their  adher-
ence.  Differential  validity  showed  an  increase  in  adherence
as  patients  aged,  and  patients  exhibited  a  higher  adherence
to  longer  treatments.  This  latter  fact  should  be  under-
stood  as  a  post  hoc  effect  when  evaluating  intentional
groups.  In  other  words,  we  did  not  assess  a  sample  over
time  and  note  that  treatment  adherence  decreased  over
time;  instead,  we  used  a  cross-sectional  study  to  evalu-
ate  patients  receiving  medical  treatment  who  continued
attending  consultations  to  follow  their  treatment.  This  is
particularly  clear  in  patients  with  the  most  chronic  disor-
ders:  bipolar  disorder  and  schizophrenia,  who  realize  that
regular  attendance  to  consultations  is  a  way  of  better  man-
aging  their  disease.
We  did  not  observe  any  relationships  between  gender,
education  level  or  complexity  of  treatment  and  non-
adherence  in  our  sample,  probably  as  a  result  of  the
particular  characteristics  of  the  type  of  sample  studied.
Moreover,  the  MMAS-8  was  able  to  differentiate  between
the  different  mental  disorder  diagnosis  groups.  As  regards
convergent  validity,  locus  of  control  exhibited  distinctive
correlation  patterns  with  adherence  and  psychological  reac-
tance  was  negatively  correlated  with  adherence.  Results
conﬁrmed  that  psychiatric  outpatients  with  higher  psycho-
logical  reactance  (both  affective  and  cognitive)  were  more
likely  to  be  non-adherent  than  patients  with  lower  levels
of  psychological  reactance.  Individuals  with  low  reactance
generally  follow  instructions  and  advice,  while  individ-
uals  with  high  reactance  frequently  confront  any  guidance
or  assistance.  People  with  high  psychological  reactance
typically  tend  to  focus  on  their  own  resources,  personal  deci-
sions  and  initiatives  (i.e.,  internal  attribution  of  change),
t
n
a
while  people  with  low  psychological  reactance  frequently
eek  external  help  and  support  to  achieve  their  goals  (i.e.,
xternal  attribution  of  change).
Our  study  has  some  limitations  related  to  the  method-
logy  used  that  should  be  noted.  First,  although  a  high
ate  of  participation  was  recorded  in  our  study,  our  results
ay  be  affected  by  a selection  bias.  Speciﬁcally,  there  may
e  differences  in  psychological  features  between  individ-
als  who  agreed  to  participate  in  the  study  and  those  who
id  not.  Second,  our  study  included  a  convenience  sample
f  consecutive  psychiatric  outpatients  attending  community
ental  health  centers  and  therefore  may  not  be  representa-
ive  of  the  entire  population  of  psychiatric  patients.  Third,
ll  the  questionnaires  applied  were  self-reports,  which  car-
ies  a  potential  risk  of  misstatement  or  response  biases.
 further  limitation  is  the  fact  that  we  only  used  one
ethod  to  estimate  adherence.  It  should  be  noted  that
any  direct  and  indirect  methods  are  currently  available
or  measuring  adherence.  Each  method  has  advantages  and
isadvantages,  and  no  method  is  considered  to  be  the  gold
tandard.
The  present  study  advances  the  evidence  of  the  validity
f  the  Spanish  version  of  MMAS-8  in  psychiatric  outpatients
nd  broadens  previous  research  demonstrating  the  inter-
al  reliability  and  predictive  validity  of  the  MMAS-8  with
egard  to  psychiatric  drug  treatment  adherence.  This  eight-
tem  self-report  questionnaire  is  simple  and  can  be  included
nto  routine  psychiatric  clinical  practice.  It  is  likely  to  be
seful  to  identify  patients  at  risk  for  medication  adher-
nce  issues  and  speciﬁcally  low  adherence  in  outpatient
sychiatric  care.  Further  studies  should  focus  on  testing
ther  psychometric  properties  of  the  instrument  and  war-
ant  better  assess  medication-taking  behaviors  in  different
opulation  and  settings.
ppendix 1. Eight-item Morisky Medication
dherence Scale
elow  is  a  list  of  statements.  Please  indicate  the  extent
o  which  you  agree  or  disagree  with  them  by  circling  the
umber  of  the  appropriate  box.  There  are  no  right  or  wrong
nswers.  Please  give  honest  answers;  otherwise  the  result
ould  not  be  valid.
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Regarding  your  psychiatric  treatment. .  ..
medicyourtaketoforgetsometimesyouDo1.
2. Peo ple  sometimes miss  ta king their  medicati 
Over the past  2 weeks,  were there any days  wh 
3. Have yo u ever  cut back or st opped ta king yo
doctor because you felt worse when you took i
4. When yo u travel  or lea ve home, do you som 
medication? 
yesterday?medicationyouralltakeyouDid5.
6. When you  feel  like  your symp tom s are  unde 
taking your medicati on? 
7. Tak ing medication  ever y day is a real inconv 
ever feel  hass led  about  stick ing  to  your  trea tme 
8. How often do you have difficulty remember
Never/Rarely……… …..........   
Once in  a while……… ……...   
Someti mes………… ………..   
Usually………………………. 
All the time………………….. 
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